These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 15934970

  • 1. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jul; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 5. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 6. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [Abstract] [Full Text] [Related]

  • 7. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ.
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [Abstract] [Full Text] [Related]

  • 8. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB.
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [Abstract] [Full Text] [Related]

  • 9. The need for better control of secondary hyperparathyroidism.
    Locatelli F.
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [Abstract] [Full Text] [Related]

  • 10. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [Abstract] [Full Text] [Related]

  • 12. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J, CONTROL Investigators.
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
    Ogata H, Koiwa F, Ito H, Kinugasa E.
    Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
    [Abstract] [Full Text] [Related]

  • 14. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD.
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [Abstract] [Full Text] [Related]

  • 15. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [Abstract] [Full Text] [Related]

  • 16. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Feb; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 18. [What are the actual indications for a surgical parathiroidectomy?].
    Torres PU.
    Nephrol Ther; 2005 Dec; 1 Suppl 4():S342-50. PubMed ID: 17373206
    [Abstract] [Full Text] [Related]

  • 19. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A, Morinière P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PF.
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [Abstract] [Full Text] [Related]

  • 20. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.